microRNA在乳腺癌耐药中的作用

doi:10.11904/j.issn.1002-3070.2017.03.017

Abstract

Abstract: Breast cancer is a major disease which threatens the health of women around the world.Breast cancer patients have acquired resistance to existing treatment methods become the current clinical problems.MicroRNA(miRNA)is an endogenous non-coding RNA that participates in the regulation of a variety of biological processes,including cell proliferation,invasion,metastasis,epithelial interstitial transformation and drug resistance.Acquired resistance includes a variety of complex mechanisms that can affect the expression of cell-associated proteins through the abnormal expression of specific microRNAs,the binding of antineoplastic agents to the corresponding target,and the pathways associated with apoptosis.This article will focus on the expression of abnormal microRNA in acquired drug resistance which was caused by endocrine therapy,chemotherapy and molecular targeted therapy of breast cancer.miRNAs are considered as promising biomarkers and targets for diagnosis,treatments for acquired drug resistance of breast cancer.

Key words: Breast cancer, microRNA, Drug resistance

CLC Number:

R737.9

HUANG Jian,PANG Hui,SONG Yuhang,CAI Li. The role of microRNA in drug resistance of breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 272-276.

References

1 Ahmad A.Pathways to breast cancer recurrence[J].ISRN Oncol,2013,2013:290568.
2 Wu X,Somlo G,Yu Y,et al.De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer[J].J Transl Med,2012,10:42.
3 Garofalo M,Croce CM.MicroRNAs as therapeutic targets in chemoresistance[J].Drug Resist Updat,2013,16(3-5):47-59.
4 Di Leva G,Croce CM.Roles of small RNAs in tumor formation[J].Trends Mol Med,2010,16(6):257-267.
5 Lee Y,Ahn C,Han J,et al.The nuclear RNase III Drosha initiates microRNA processing[J].Nature,2003,425(6956):415-419.
6 Takahashi RU,Miyazaki H,Ochiya T.The roles of microRNAs in breast cancer[J].Cancers(Basel),2015,7(2):598-616.
7 Sabnis GJ,Goloubeva O,Chumsri S,et al.Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole[J].Cancer Res,2011,71(5):1893-1903.
8 Ma CX,Adjei AA,Salavaggione OE,et al.Human aromatase:gene resequencing and functional genomics[J].Cancer Res,2005,65(23):11071-11082.
9 Hayes EL,Lewis-Wambi JS.Mechanisms of endocrine resistance in breast cancer:an overview of the proposed roles of noncoding RNA[J].Breast Cancer Res,2015,17:40.
10 Iorio MV,Casalini P,Piovan C,et al.Breast cancer and microRNAs:therapeutic impact[J].Breast,2011,20(Suppl 3):63-70.
11 Lyng MB,Laenkholm AV,Sokilde R,et al.Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy:a DBCG study[J].PLoS One,2012,7(5):e36170.
12 Miller TE,Ghoshal K,Ramaswamy B,et al.MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1[J].J Biol Chem,2008,283(44):29897-29903.
13 Cittelly DM,Das PM,Spoelstra NS,et al.Downregulation of miR-342 is associated with tamoxifen resistant breast tumors[J].Mol Cancer,2010,9:317.
14 Shi W,Gerster K,Alajez NM,et al.MicroRNA-301 mediates proliferation and invasion in human breast cancer[J].Cancer Res,2011,71(8):2926-2937.
15 Dunn C,Keam SJ.Letrozole:a pharmacoeconomic review of its use in postmenopausal women with breast cancer[J].Pharmacoeconomics,2006,24(5):495-517.
16 Masri S,Liu Z,Phung S,et al.The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells[J].Breast Cancer Res Treat,2010,124(1):89-99.
17 Vilquin P,Donini CF,Villedieu M,et al.MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer[J].Breast Cancer Res,2015,17:13.
18 Buzdar AU,Robertson JF.Fulvestrant:pharmacologic profile versus existing endocrine agents for the treatment of breast cancer[J].Ann Pharmacother,2006,40(9):1572-1583.
19 Di Leo A,Jerusalem G,Petruzelka L,et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J].J Clin Oncol,2010,28(30):4594-4600.
20 Xin F,Li M,Balch C,et al.Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance[J].Bioinformatics,2009,25(4):430-434.
21 Rao X,Di Leva G,Li M,et al.MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways[J].Oncogene,2011,30(9):1082-1097.
22 Yu X,Luo A,Liu Y,et al.MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy[J].Mol Cancer,2015,14:208.
23 Pan ST,Li ZL,He ZX,et al.Molecular mechanisms for tumour resistance to chemotherapy[J].Clin Exp Pharmacol Physiol,2016,43(8):723-737.
24 Zhu Y,Yu F,Jiao Y,et al.Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5[J].Clin Cancer Res,2011,17(22):7105-7115.
25 Tryndyak VP,Beland FA,Pogribny IP.E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells[J].Int J Cancer,2010,126(11):2575-2583.
26 Bao L,Hazari S,Mehra S,et al.Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298[J].Am J Pathol,2012,180(6):2490-2503.
27 Zhong S,Li W,Chen Z,et al.MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells[J].Gene,2013,531(1):8-14.
28 Wang H,Tan G,Dong L,et al.Circulating MiR-125b as a marker predicting chemoresistance in breast cancer[J].PLoS One,2012,7(4):e34210.
29 Gu X,Li JY,Guo J,et al.Influence of miR-451 on drug resistances of paclitaxel-resistant breast cancer cell line[J].Med Sci Monit,2015,21:3291-3297.
30 Sha LY,Zhang Y,Wang W,et al.MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer[J].Eur Rev Med Pharmacol Sci,2016,20(11):2201-2208.
31 Zhao ZL,Cai Y,Wang YY,et al.Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells[J].Zhejiang Da Xue Xue Bao Yi Xue Ban,2015,44(4):400-409.
32 Brufsky A.Trastuzumab-based therapy for patients with HER2-positive breast cancer:from early scientific development to foundation of care[J].Am J Clin Oncol,2010,33(2):186-195.
33 Baselga J,Gelmon KA,Verma S,et al.Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J].J Clin Oncol,2010,28(7):1138-1144.
34 Scott GK,Goga A,Bhaumik D,et al.Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b[J].J Biol Chem,2007,282(2):1479-1486.
35 Leivonen SK,Sahlberg KK,Makela R,et al.High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth[J].Mol Oncol,2014,8(1):93-104.
36 Gong C,Yao Y,Wang Y,et al.Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer[J].J Biol Chem,2011,286(21):19127-19137.
37 Iorio MV,Casalini P,Piovan C,et al.MicroRNA-205 regulates HER3 in human breast cancer[J].Cancer Res,2009,69(6):2195-2200.
38 Venturutti L,Cordo Russo RI,Rivas MA,et al.MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1[J].Oncogene,2016,35(48):6189-6202.
39 Corcoran C,Rani S,Breslin S,et al.miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer[J].Mol Cancer,2014,13:71.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[3]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[4]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[5]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[6]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[7]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.
[8]	LIN Rongjie, YIN Hang, ZHOU Yunfeng. Effect of ON123300 on ER+ human breast cancer MCF-7 cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 193-197.
[9]	FAN Ningning, GENG Jingshu. The expression and role of LncRNA MEG3 in human glioma cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 219-223.
[10]	LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.
[11]	ZHENG Wei, XU Shouping, PANG Da. Expression,prognosis and function of long chain non-coding RNA-Linc00152 in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 7-13.
[12]	YIN Yulian, ZHANG Weihong, ZHOU Yue, YE Meina, CHEN Hongfeng. Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 14-18.
[13]	XIN He, WANG Chuanzhuo, LIU Zhaoyu. Research progress on the relationship between microRNA-196a and tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 42-46.
[14]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[15]	CHEN Zhuo, KONG Yiran. Effect of silencing UHRF1 on proliferation and metastasis of breast cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 512-518.

The role of microRNA in drug resistance of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments